Generation of induced pluripotent stem cells (iPSCs) via the ectopic expression of reprogramming factors is a simple, advanced, yet often inefficient, slow, stochastic technology due to the overexpression of multiple genes. Scientists of Creative Biolabs have used almost all available approaches for the delivery of reprogramming factors. Creative Biolabs has developed streamed-line protocols for efficient iPSC generation with viral vectors, DNA (plasmid), RNA and recombinant proteins. Each of these services will be provided with a comprehensive report suitable for publications.
In 2006, Yamanaka's team first produced iPSCs from mouse embryonic fibroblasts (MEFs) by introducing four factors Oct4, Sox2, KLF4, and c-myc. iPSCs have similar pluripotency and self-renewal capacity to embryonic stem cells (ESCs). When establishing a method for efficiently generating and differentiating iPSCs, regenerative medicine with transplantation of iPSCs-derived cells, tissues, or organs will approach reality. One advantage of using autografts from patient-derived iPSCs is that the risk of immune rejection is very low. iPSCs can be generated from various types of cells with transduction of defined transcription factors.
Due to the high reprogramming efficiency, hematopoietic cells can be obtained in a minimally invasive way and will be a good donor source for establishing iPSCs. Various methods for establishing iPSCs from hematopoietic cells have been reported.
iPSCs can be generated not only from normal cells but also from several types of tumor cells. Disease-specific iPSCs, especially from hematological malignancies, are useful because primary samples of hematological malignancies are usually difficult to be expanded. After the establishment of iPSCs with malignant cell genome abnormalities, iPSCs with genetic abnormalities can be distinguished and continuously obtained. They will be used in studies that require large numbers of living cells, proteomes, epigenome and transcriptome profiling, leukemia stem cell analysis or drug screening assays. iPSCs from hematological malignancies have been established from myeloproliferative neoplasms including chronic myelogenous leukemia (CML) and JAK2-V617F mutation-positive polycythemia vera (PV). iPSC technology has great potential to promote oncology research based on patient samples.
Generally steps in a reprogramming experiment include tissue selection, proceeding through iPSC generation, possible transgene excision to produce iPSC cells that are ready for use in a translational setting. Creative Biolabs is dedicated to providing several viable and cost-effective methods for pluripotent stem cells (iPSC) reprogramming. We employ advanced iPSC reprogramming factor delivery strategy by virus, iPSC reprogramming factor delivery by integration-free vectors, as well as other iPSC reprogramming methods (mRNA, protein) to help you obtaining the desired iPSC.
Conventional iPSC factor reprogramming is based on integrating vectors with the problems of cell death, residual expression, and re-activation of reprogramming factors, immunogenicity, uncontrolled silencing of transgenes, and insertional mutagenesis. Methods of factor reprogramming fall into two broad categories: chemical and transgene reprogramming. It has been reported that many small molecules promote reprogramming when used with the classical reprogramming factors.
There are genomic integration methods and integration-free methods that can be used for the induction of reprogramming factors. The genomic integration methods can induce iPS cells easily and efficiently. Therefore, they are useful for basic research. The induction methods are also divided into four categories based on the types of vector being used, i.e. a virus, DNA (plasmid), RNA or protein.
Chemical Reprogramming
Small molecules that regulate specific targets involved in signaling, metabolic, transcriptional, and epigenetic mechanisms have become valuable tools for detecting basic stem cell biology and manipulating stem cell fate, state, or function in vitro and in vivo. Rational design and/or screening of useful compounds have been used for enhancing cell-based therapy and/or promoting the development of therapeutic drugs targeting endogenous stem and progenitor cells to treat degenerative diseases, cancer, and injuries.
Small molecules have many unique advantages over genetic manipulations:
With 100% success rate, Creative Biolabs is guaranteed to provide highly efficient generation services of different cells into iPSC with our advanced technology. contact us today to discuss your iPSC generation project with a technical specialist.
For Research Use Only. Not For Clinical Use.